BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32321104)

  • 1. Synergic effect of simvastatin in combination with amphotericin B against environmental strains of Cryptococcus neoformans from northeastern Brazil: a prospective experimental study.
    Silva THS; Araújo CV; Santos KMDC; Alves NDS; Gomes THS; Silva AKFE; Silva NCLDS; Damasceno Júnior ECB; Carvalho AMA; Mendes MGA; Caminha HB; Daboit TC; Ferreira TB; Andrade-Silva LE; Silva-Vergara ML; Ferreira-Paim K; Fonseca FM
    Sao Paulo Med J; 2020; 138(1):40-46. PubMed ID: 32321104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
    Silva PR; Rabelo RA; Terra AP; Teixeira DN
    Rev Soc Bras Med Trop; 2008; 41(2):158-62. PubMed ID: 18545836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
    Franzot SP; Casadevall A
    Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.
    Souza LK; Fernandes Ode F; Kobayashi CC; Passos XS; Costa CR; Lemos JA; Souza-Júnior AH; Silva Mdo R
    Rev Inst Med Trop Sao Paulo; 2005; 47(5):253-6. PubMed ID: 16302107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.
    Nooney L; Matthews RC; Burnie JP
    Diagn Microbiol Infect Dis; 2005 Jan; 51(1):19-29. PubMed ID: 15629225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans.
    Hai TP; Van AD; Ngan NTT; Nhat LTH; Lan NPH; Vinh Chau NV; Thwaites GE; Krysan D; Day JN
    Mycoses; 2019 Sep; 62(9):818-825. PubMed ID: 31173410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
    Tan L; Shi H; Chen M; Wang Z; Yao Z; Sun Y
    J Mycol Med; 2022 Mar; 32(1):101227. PubMed ID: 34800920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirão Preto, São Paulo, Brazil.
    Pedroso RS; Ferreira JC; Candido RC
    Mem Inst Oswaldo Cruz; 2006 May; 101(3):239-43. PubMed ID: 16862315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
    Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
    J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATI-2307 Exhibits Equivalent Antifungal Activity in
    Gerlach ES; Altamirano S; Yoder JM; Luggya TS; Akampurira A; Meya DB; Boulware DR; Rhein J; Nielsen K
    Front Cell Infect Microbiol; 2021; 11():695240. PubMed ID: 34249782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin inhibits planktonic cells and biofilms of Candida and Cryptococcus species.
    Brilhante RS; Caetano EP; Oliveira JS; Castelo-Branco Dde S; Souza ER; Alencar LP; Cordeiro Rde A; Bandeira Tde J; Sidrim JJ; Rocha MF
    Braz J Infect Dis; 2015; 19(5):459-65. PubMed ID: 26119850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
    Burgess DS; Hastings RW
    Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular typing of environmental Cryptococcus neoformans/C. gattii species complex isolates from Manaus, Amazonas, Brazil.
    Alves GS; Freire AK; Bentes Ados S; Pinheiro JF; de Souza JV; Wanke B; Matsuura T; Jackisch-Matsuura AB
    Mycoses; 2016 Aug; 59(8):509-15. PubMed ID: 27005969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
    Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
    Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
    Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of Sensititre YeastOne and VITEK 2 against the Clinical and Laboratory Standards Institute M27-E4 reference broth microdilution method for the antifungal susceptibility testing of Cryptococcus neoformans and Cryptococcus gattii.
    Zhang M; Zhou Z; Wang D; Zhou A; Song G; Chen X; Guo J; Wu W
    Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35099022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.